ADMA Biologics Inc vs iShares Semiconductor ETF — how do they compare? ADMA Biologics Inc trades at $9.94 (market cap $2.22B), while iShares Semiconductor ETF trades at $551.42. The key difference: iShares Semiconductor ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | SOXX | |
|---|---|---|
Market Cap | $2.22B | — |
Sector | Health | Sector/Thematic |
52-Week High | $20.38 | $655.01 |
52-Week Low | $7.60 | $241.68 |
Enterprise Value | $2.29B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
SOXX, the iShares Semiconductor ETF, trades at $550.61, up 3.88% in the last session, with a bullish technical signal driven by moving averages. Recent news highlights sector volatility, including a 21% plunge in July due to headwinds like short-seller commentary and competitive pressures, though major cloud company growth supports AI spending optimism. The ETF's concentration in 30 semiconductor stocks contrasts with broader tech diversification options.
Outlook hinges on semiconductor demand from AI and data centers, with potential from U.S. policy support, but risks include tariff impacts, high valuation concerns, and sector rotation. Investors face trade-offs between SOXX's focused exposure and broader, lower-fee alternatives amid ongoing market efficiency and inflow trends.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →